// App-Quantinova.ai

TPS7573 : Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL).

Researchers

Presenter

  • Wojciech Jurczak

Principal Investigators

  • Pier Luigi Zinzani

  • David Cunningham

  • Sharon Yavrom

  • Wenying Huang

  • Igor Gorbatchevsky

  • Vincent Ribrag

Medical Centers

  • National Institute of Oncology, Kraków, Poland

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Tocagen, Inc., San Diego, CA

  • MEI Pharma, Inc., San Diego, CA

  • Iovance Biotherapeutics, Whippany, NJ, Institut Gustave Roussy, Villejuif, France

Locations

  • Poland

  • Italy

  • United Kingdom

  • France

Companies

  • Tocagen Inc.

  • MEI Pharma, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • Lenalidomide

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03768505

  • NCT04745832

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved